Duncan Barbara Gayle 4
4 · HALOZYME THERAPEUTICS, INC. · Filed May 2, 2025
Insider Transaction Report
Form 4
Duncan Barbara Gayle
Director
Transactions
- Award
Option to Purchase Common Stock
2025-05-01+5,750→ 5,750 totalExercise: $60.03Exp: 2035-05-01→ Common Stock (5,750 underlying) - Award
Common Stock
2025-05-01+4,165→ 19,919 total
Footnotes (2)
- [F1]Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
- [F2]Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.